Semaglutide Cuts Childhood Obesity by 40% in Landmark Trial as GLP-1 Prescriptions Surge

A landmark clinical trial delivered the strongest evidence yet that the blockbuster weight-loss drug Wegovy works in young children. In the STEP Young study announced Monday, Novo Nordisk reported that 40.4% of children aged 6 to under 12 treated with semaglutide were no longer classified as having obesity after 68 weeks of once-weekly injections, assuming full adherence. All participants also received lifestyle modifications including diet and exercise. "We are...